Icatibant Medical Valley (Icatibant)

Icatibant is a selective competitive antagonist of the bradykinin B2 receptor. By blocking this receptor, it prevents bradykinin‑induced vasodilation and increased vascular permeability, which are the primary mechanisms that cause swelling during hereditary angioedema attacks.

The dose of icatibant is determined by the prescribing healthcare professional based on the patient’s clinical condition and regulatory guidelines. The prescriber will decide the appropriate amount and frequency for each individual case.

Safety data for icatibant in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against any possible risks before prescribing it to pregnant or breastfeeding women, and use it only if clearly indicated.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain handling if needed) and import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas other acute HAE therapies, such as C1‑esterase inhibitor concentrates, replace a deficient protein. Icatibant directly blocks the downstream effects of bradykinin, offering a rapid, targeted approach that does not require plasma‑derived products.

Icatibant should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability.

Icatibant is given by subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a trained healthcare professional or, in some cases, by the patient after proper instruction.

The most serious risks include anaphylaxis, severe hypotension, and paradoxical worsening of angioedema. Patients should be monitored closely after injection for any signs of these reactions, and emergency medical care should be sought immediately if they occur.

Icatibant should not be used in individuals with known hypersensitivity to the drug or any of its excipients. Caution is also advised for patients with severe cardiovascular disease or those taking ACE inhibitors, as the risk of adverse reactions may be increased.